BiotechTube

REC-4881

Phase 2Terminated
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

AXIN1 Gene Mutation

Conditions

AXIN1 Gene Mutation, APC Gene Mutation, Solid Tumor

Trial Timeline

Jan 15, 2024 → Feb 24, 2025

NCT ID
NCT06005974

About REC-4881

REC-4881 is a phase 2 stage product being developed by Recursion Pharmaceuticals for AXIN1 Gene Mutation. The current trial status is terminated. This product is registered under clinical trial identifier NCT06005974. Target conditions include AXIN1 Gene Mutation, APC Gene Mutation, Solid Tumor.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06005974Phase 2Terminated

Other Products from Recursion Pharmaceuticals

REC-2282 + PlaceboPhase 2/3
60
REC-3964Phase 2
47
REC-994 + PlaceboPhase 2
47
REC-1245Phase 1/2
36
REC-4881 + PlaceboPhase 1/2
36